arGentis Issued Key Patent Related to Treating Fibrosing Diseases by Induction of Immune Tolerance

arGentis Issued Key Patent Related to Treating Fibrosing Diseases by Induction of Immune Tolerance
Memphis, TN-- arGentis Pharmaceuticals, LLC  recently  announced the issuance of United States patent 7,718,765, titled "Methods for Treating Fibrosing Diseases by Induction of Immune Tolerance."  The issued patent, based on the seminal research of Arnold E. Postlethwaite, MD and Andrew H. Kang, MD, at the University of Tennessee Health Science Center, generally claims methods of treating fibrosing diseases by induction of immune tolerance utilizing orally administered, antigen-specific immunotherapies.  
"This patent further expands our autoimmune IP estate and broadens the applicability of treating other fibrosing diseases through the induction of immune tolerance," said J. Edward "Ted" Townsend, III, Chief Operating Officer of arGentis. "We look forward to investigating the full potential of immune tolerance as an effective therapeutic pathway for various autoimmune disease indications."
The issued claims include various immunotherapy combinations used to treat scleroderma, a chronic autoimmune disease of the connective tissue.   Additional fibrosing diseases such as vascular fibrosis, as occurs in atherosclerosis, and fibrosis involved in the skin, liver, kidneys, lung, heart and gastrointestinal tract are addressed in other patent applications on file and in process.

arGentis is finalizing plans to conduct a Phase IIb trial for their scleroderma therapy, ARG201, and has begun a Phase I trial studying the use of an altered peptide ligand to treat Rheumatoid Arthritis.

About arGentis Pharmaceuticals
arGentis Pharmaceuticals is a privately-held, diversified, biopharmaceutical company dedicated to the licensing, development and commercialization of novel classes of therapies to treat chronic diseases in autoimmunity and ophthalmology. arGentis' drug R&D programs are focused on treating underlying mechanisms of inflammatory conditions through utilization of oral and transdermal compounds.

For more information, contact:
Ted Townsend, Chief Operating Officer, arGentis Pharmaceuticals, LLC